Altos Labs launches with $3B and Hal Barron as incoming CEO

Altos Labs/Cellular rejuvenation programming

Altos Labs launched with $3 billion committed to cellular rejuvenation programming, aiming to reset cells to a younger state to reverse disease. It named GSK's Hal Barron as incoming CEO effective August 2022, opened institutes in the Bay Area, San Diego and Cambridge (UK), and signed Nobel laureates including Shinya Yamanaka, whose reprogramming factors underpin its scientific strategy.

• $3 billion committed funding, with operations across San Francisco Bay Area, San Diego, and Cambridge, UK.
• Advisory board includes Nobel laureates: Frances Arnold, Jennifer Doudna, Shinya Yamanaka.
• Rick Klausner and Hans Bishop founded Altos; Hal Barron to join as CEO August 2022.
• Goal: reset cells to younger state via reprogramming to reverse age-related damage and disease.